Professional background
Professor Andrea Malaspina is a consultant neurologist at The National Hospital for Neurology and Neurosurgery and a professor of neurology, as well as the director of the BRC UCL Queen Square MND Centre. He leads a multidisciplinary team dedicated to improving diagnosis, care, and long‑term outcomes for people living with motor neuron disease (MND), also known internationally as ALS (amyotrophic lateral sclerosis), along with other complex neuromuscular conditions.
With more than 25 years of clinical practice in general neurology, Professor Malaspina has extensive expertise in neuromuscular disorders and neurodegenerative diseases, particularly MND/ALS. He provides specialist assessments, second opinions, and personalised treatment plans for patients in both NHS and private settings, supporting individuals with complex and progressive neurological conditions.
After completing a PhD in molecular neurobiology at Imperial College London, he became a consultant neurologist at Barts Health. There, he founded the local MND Care and Research Centre, combining hands‑on clinical work with active research into neuromuscular and motor neuron disorders. He was appointed clinical senior lecturer at Barts and The London School of Medicine in 2012 and promoted to professor of neurology in 2019. During this time, he led MND research across the North Thames Clinical Research Network and directed the Neurodegeneration Research Group at the Blizard Institute in London.
Specialties
Research interests
Professor Malaspina leads a multidisciplinary research programme focused on discovering new biomarkers and therapeutic targets in motor neuron disease (MND/ALS) and related neurodegenerative conditions.
His work aims to identify biological signals that may:
- Indicate a person’s risk of developing MND
- Predict when symptoms may begin and how the disease may progress
- Help clinicians understand how well a treatment is working
His research uses a multimodal, translational approach that links laboratory science, clinical neurology, and precision medicine. By studying the molecular and cellular mechanisms that drive MND/ALS, his work supports the development of new diagnostic tools and more personalised treatment strategies.
Professor Malaspina has been instrumental in establishing large‑scale biobanking initiatives for neurodegenerative diseases, allowing researchers to analyse genomic, proteomic, and clinical data together. He also leads efforts to develop highly sensitive biochemical tests that can classify disease subtypes and provide reliable, trial‑ready biomarkers. This work is contributing to the design of innovative therapies and platform trials that are reshaping the landscape of MND/ALS research and treatment.
Languages spoken
Italian
French